Your browser doesn't support javascript.
loading
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.
Lin, Shan; Larrue, Clément; Scheidegger, Nastassja K; Seong, Bo Kyung A; Dharia, Neekesh V; Kuljanin, Miljan; Wechsler, Caroline S; Kugener, Guillaume; Robichaud, Amanda L; Conway, Amy Saur; Mashaka, Thelma; Mouche, Sarah; Adane, Biniam; Ryan, Jeremy A; Mancias, Joseph D; Younger, Scott T; Piccioni, Federica; Lee, Lynn H; Wunderlich, Mark; Letai, Anthony; Tamburini, Jérôme; Stegmaier, Kimberly.
Affiliation
  • Lin S; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Larrue C; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Scheidegger NK; Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Seong BKA; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Dharia NV; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Kuljanin M; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Wechsler CS; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Kugener G; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Robichaud AL; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Conway AS; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mashaka T; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Mouche S; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Adane B; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Ryan JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Mancias JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Younger ST; Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Piccioni F; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Lee LH; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Wunderlich M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Letai A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tamburini J; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Stegmaier K; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Cancer Discov ; 12(2): 432-449, 2022 02.
Article in En | MEDLINE | ID: mdl-34531254
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Xenograft Model Antitumor Assays / Precision Medicine / CRISPR-Cas Systems / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Xenograft Model Antitumor Assays / Precision Medicine / CRISPR-Cas Systems / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2022 Type: Article